Coherus BioSciences (CHRS) Stock Analysis & AI Equity Report
Coherus BioSciences (CHRS) overview
Coherus BioSciences (CHRS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 42.2m and operating profit of USD -181m; the year-end share price was 1.42 USD and market capitalisation was USD 172m. Coherus BioSciences is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Coherus BioSciences's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Coherus BioSciences
Coherus Oncology is a commercial-stage oncology company that commercializes LOQTORZI in the United States and develops cancer medicines. LOQTORZI is an approved PD-1 inhibitor for certain adults with nasopharyngeal carcinoma. Its clinical pipeline includes casdozokitug, an investigational IL-27 antagonist, and tagmokitug, an investigational CCR8-targeting antibody. The company holds global development and commercialization rights to both candidates.
Generate the Coherus BioSciences report
Coherus BioSciences is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Coherus BioSciences and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Coherus BioSciences
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.